| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53580b74d31a7a1812ff95568ac819c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_58f52de725a0cbb9de9b6446dc7375f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f84ea23f26b499f1bc9459bc99cd56fe |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 |
| filingDate |
2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7deb419b220cbe2315dcfcd56bb5cb25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_776002d51dd6dd980dc04f5824c49567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_140e8237006cffd91c04b49ef612ee0a |
| publicationDate |
2017-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017068070-A1 |
| titleOfInvention |
Nurr1:rxr activating compounds for simultaneous treatment of symptoms and pathology of parkinson's disease |
| abstract |
The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXRα heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXRα function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXRα activating agents. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3831810-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020027150-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020189788-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112513011-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112513011-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11261154-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3927330-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7323913-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4029857-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7306392-B2 |
| priorityDate |
2015-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |